Brain Penetrant NLRP3 Inhibitors: The Discovery of a Panacea?
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c02846 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von David Harrison. Beteiligte Einrichtung: NodThera Ltd., Suite 8, The Mansion, Chesterford Research Park, Little Chesterford, Saffron Walden, Essex CB10 1XL, United Kingdom. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Drug Discovery, Brain. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
The NLRP3 inflammasome has attracted much interest as a drug target; however, many of the first wave of inhibitors were derived from a single aryl sulfonylurea starting point. The physicochemical properties of this molecule and most derivatives are not amenable to high brain penetration, thus limiting their potential effectiveness against disease targets where this is required. The disclosure of a novel pyridazine phenol scaffold facilitated a second wave of research toward brain-penetrant molecules, which may enable the discovery of novel treatments for Alzheimer's disease, Parkinson's disease, multiple sclerosis and cardiometabolic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- NodThera Ltd., Suite 8, The Mansion, Chesterford Research Park, Little Chesterford, Saffron Walden, Essex CB10 1XL, United Kingdom.
ORCID-Profile: David Harrison
Zitieren
APA
Harrison, D. (2024). Brain Penetrant NLRP3 Inhibitors: The Discovery of a Panacea?. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02846
Vancouver
Harrison D. Brain Penetrant NLRP3 Inhibitors: The Discovery of a Panacea?. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c02846
BibTeX
@article{Harrison2024,
author = {Harrison, David},
title = {Brain Penetrant NLRP3 Inhibitors: The Discovery of a Panacea?},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c02846}
}
EUVIMED